Community Oncology

Volume 5, Number 9, Supplement 11 (September 2008)

Current Clinical Trials

1

  

PRISM: a study of second-line panitumumab monotherapy for treatment of advanced head and neck cancer

David R. Spigel, MD

Sarah Cannon Research Institute, Nashville, TN

Patients with advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) generally have a poor prognosis, with a 5-year survival rate of 15%–30%. First-line therapy for locoregionally recurrent or metastatic SCCHN typically consists of cisplatin combined with 5-fluorouracil or docetaxel, but even with treatment, median time to disease progression is short. Few effective second-line therapy options exist for patients with recurrent or refractory disease. Panitumumab is a novel fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It is approved as a single agent for the treatment of metastatic colorectal cancer. In patients with advanced SCCHN, EGFR inhibition potentially may have a clinical benefit. An ongoing open-label phase II trial known as PRISM (Panitumumab Regimen in Second-line Monotherapy of Head and Neck Cancer) is evaluating the efficacy and safety of panitumumab monotherapy for second-line treatment of metastatic or recurrent SCCHN.

abstract full text 279 kb

© 2008 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.